Guillain-Barre Syndrome
43
4
4
17
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.7%
2 terminated out of 43 trials
89.5%
+2.9% vs benchmark
9%
4 trials in Phase 3/4
12%
2 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 17 completed trials
Clinical Trials (43)
Biomarkers in Autoimmune Disease of Nervous System
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Noninvasive Support for Acute Respiratory Failure in Guillain-Barré Syndrome
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia Gravis
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome
Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome
Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
Prognostic Indicators of Gullian-Barre Syndrome
Predictive Value of Neuromuscular Ultrasound of Cranial Nerves in Guillain-Barré Syndrome
PatientSpot Formerly Known as ArthritisPower
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
Early and Late Prognosis in Patients With Guillain-Barre Syndrome
Prognosis in Patients With Guillain-Barre Syndrome
Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome
RWE-based Treatment Patterns and Outcomes in CIDP
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil